This study investigates whether the interaction between angiotensinconverting enzyme (ACE) inhibitors or b-blockers and the ACE insertion/ deletion (I/D) polymorphism or angiotensin receptor II type 1 (AGTR1) 573C/T polymorphism modifies the risk of myocardial infarction (MI) or stroke. In total, 4097 subjects with hypertension were included in this study. The drug-gene interaction on the risk of MI or stroke was determined with a Cox proportional hazard model. The risk of MI was reduced in current users of ACE inhibitors with the AGTR1 573CT or CC genotype compared to ACE inhibitors with the AGTR1 573TT genotype (synergy index (SI):0.32; 95% confidence interval (CI): 0.14-0.70). No significant drug-gene interaction was found on the risk of stroke (SI:0.82; 95% CI: 0.44-1.52) or in b-blocker users. Also, no significant drug-gene interaction was found with the ACE I/D polymorphism. In conclusion, subjects with at least one copy of the AGTR1 573C allele might have more benefit from ACE inhibitor therapy.
Introduction
Hypertension is a common disorder affecting approximately 20% of the adult populations of most developed countries 1 and is a major risk factor for cardiovascular disease. Many physiological, biochemical and anatomical traits contribute to an individual's blood pressure level, which is homeostatically maintained through complex interactions of interrelated systems. One of these systems is the renin-angiotensin-system (RAS), which influences the expression of angiotensinogen precursor in the liver. In response to lowered blood pressure, angiotensinogen is cleaved by renin in angiotensin I. Angiotensin I is cleaved by angiotensin-converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II, which results in vasoconstriction.
Two major antihypertensive drug classes can directly interact with the RAS, that is, ACE inhibitors and b-blockers. ACE inhibitors inhibit the conversion from angiotensin I to angiotensin II, resulting in a reduction of the peripheral vascular resistance. ACE inhibitors also decrease the secretion of aldosterone, which results in a decreased sodium and water retention. b-Blockers decrease the cardiac output by inhibiting the release of renin and by acting on b1-receptors.
In the GENetics of Hypertension-Associated Treatment (GenHAT) study, no significant interaction between the ACE insertion/deletion (I/D) polymorphism and ACE inhibitor therapy on the risk of cardiovascular disease was found. 2 To our knowledge, no previous studies investigated the role of the angiotensin receptor II type 1 (AGTR1) gene on the risk of cardiovascular disease.
The objective of this study was to determine whether the risk of myocardial infarction (MI) or stroke in hypertensive patients on ACE inhibitor or b-blocker is modified by the ACE I/D polymorphism and AGTR1 573C/T polymorphism.
Results
In total, 4097 subjects with hypertension were identified during follow-up. Of these 4097 subjects, 1642 were treated with ACE inhibitors at any time, 2387 with b-blockers and 2561 with other antihypertensive drugs. A subject may have contributed to one or more categories of antihypertensive drug classes during follow-up. In total, 100% of the samples were successfully genotyped for the ACE I/D polymorphism and 98% for the AGTR1 573C/T polymorphism. Tables 1 and  2 show the baseline characteristics stratified by ACE I/D and AGTR1 573C/T genotypes.
Myocardial infarction
In total, 197 subjects experienced an MI during follow-up, of whom 30% already had had an MI before 1 January 1990. Seventy-four subjects had an MI while they were treated with b-blockers, of whom 15 had the DD genotype and 59 had the ID or II genotype (Table 3) . Forty-two subjects treated with ACE inhibitors experienced an MI, of whom 10 had the DD genotype and 32 had the ID or II genotype.
Subjects with the DD genotype who were currently treated with b-blockers had similar risk of MI compared to subjects with the DD genotype who never used b-blockers (adjusted hazard ratio (HR) ¼ 1.04; 95% confidence interval (CI): 0.47-2.31) ( Table 3) . Among subjects who never used b-blockers, the ID or II genotype was not significantly associated with the risk of MI (HR ¼ 0.89; 95% CI: 0.53-1.50). Subjects with the ID or II genotype who were currently treated with b-blockers had a nonsignificantly increased risk of MI (HR ¼ 1.55; 95% CI: 0.80-2.99) compared to subjects with the DD genotype who never used b-blockers. This HR was higher than the expected value from the joint effect of the ID or II genotype and b-blockers on a multiplicative scale (1.04 Â 0.89 ¼ 0.93). The synergy index (SI) was nonsignificantly increased (adjusted SI ¼ 1.67; 95% CI: 0.76-3.66) ( Table 4) .
Subjects with the DD genotype who were currently treated with ACE inhibitors had an increased risk of MI compared to subjects with the DD genotype who never used ACE inhibitors (HR ¼ 2.53; 95% CI: 1.06-6.03) (Table 3) . Also, in those treated with ACE inhibitors, who had the ID or II genotype, the risk of MI was increased (HR ¼ 2.73; 95% CI: 1.33-5.59). The SI for the risk of MI in ACE inhibitor users was 0.84 (95% CI: 0.36-1.97) ( Table 4) .
Of the 4015 subjects genotyped for the AGTR1 573C/T polymorphism, 197 subjects experienced an MI (Table 3) . Neither the genotype nor the use of a b-blocker was significantly associated with the risk of MI (Table 3 ). In addition, the drug-gene interaction was nonsignificant (Table 4) . Subjects with the TT genotype who were currently treated with ACE inhibitors had an increased risk of MI compared to subjects with the TT genotype who never used ACE inhibitors (HR ¼ 4.93; 95% CI: 2.22-10.95) (Table 3) . Also, the risk of MI in subjects treated with ACE inhibitors with the CT or CC genotype was increased (HR ¼ 2.31; 95% CI: 1.09-4.92). This HR was lower than expected from the joint effect of the CT or CC genotype and ACE inhibitors on a multiplicative scale (4.93 Â 1.49 ¼ 7.35). The SI was significantly reduced (SI ¼ 0.32; 95% CI: 0.14-0.70) (Table 4) . However, we did not observe an allele dose-response effect (CT versus TT genotype SI ¼ 0.35; 95% CI: 0.15-0.82 and CC versus TT genotype SI ¼ 0.59; 95% CI: 0.24-1.49). Additional analyses in which adjustments were made for systolic blood pressure level, diastolic blood pressure level, history of angina, use of acetylsalicylic acid (ASA), use of coumarins, use of NSAIDs, use of antidiabetic medication and a history of stroke and smoking yielded similar results and were therefore not shown. In addition, the exclusion of all subjects who had an MI before 1990 yielded similar results and were therefore not shown. When the analysis was repeated with other antihypertensive drug classes (that is, low-ceiling diuretics, high-ceiling diuretics or calcium antagonists), there was a significant interaction between the AGTR1 573C/T polymorphism and high-ceiling diuretics (SI ¼ 0.39; 95% CI: 0.17-0.88).
When we combined the risk alleles (ID or II and CT or TT) of the two polymorphisms, the risk of MI was significantly increased in ACE inhibitor users (Table 5 ). In addition, both risk alleles increased the risk of MI (HR ¼ 1.47; 95% CI: 1.00-2.14) in non-ACE inhibitor users compared to non-ACE inhibitor users with 0 or no risk alleles (DD and CC; ID or II and CC; DD and CT or TT). This effect was not seen in non-b-blocker users (HR ¼ 1.02; 95% CI: 0.63-1.65).
Nonetheless, the SIs were nonsignificant (b-blocker SI ¼ 1.23; 95% CI: 0.66-2.28; ACE inhibitors SI ¼ 0.53; 95% CI: 0.25-1.11).
Stroke
In total, 382 subjects who were genotyped for the ACE I/D polymorphism experienced a stroke during follow-up, of whom 14% already had had a stroke before 1 January 1990. Of these 382 subjects, 108 had a stroke when they were treated with a b-blocker, of whom 24 had the DD genotype. In total, 68 subjects experienced a stroke during ACE inhibitor therapy, of whom 12 had the DD genotype (Table 6) .
To investigate the possible interaction between b-blocker or ACE inhibitor users and the ACE I/D polymorphism on the risk of stroke, participants were grouped by current use and genotype group ( Table 6 ). The interaction between current use of b-blocker and the ACE I/D polymorphism on the risk of stroke was nonsignificant (SI ¼ 1.10; 95% CI: 0.62-1.94) ( Table 7 ). The SI in ACE inhibitor users was also nonsignificantly increased (SI ¼ 1.76; 95% CI: 0.88-3.50) ( Table 7) .
In total, 344 subjects who were genotyped for the AGTR1 573C/T polymorphism experienced a stroke during followup. Of these 344 subjects, 103 had a stroke when they were treated with a b-blocker, and 64 during ACE inhibitor therapy ( Table 5) . The interaction between current use of b-blockers and the 573C/T polymorphism on the risk of stroke was only borderline significant (SI ¼ 1.80; 95% CI: 1.00-3.24). Analyses with only ischemic strokes (n ¼ 188) were similar but no longer significant. In addition, there was no allele dose-response effect. There was no significant interaction between ACE inhibitor use and the 573C/T polymorphism (SI ¼ 0.82; 95% CI: 0.44-1.52).
Additional analyses in which adjustments were made for systolic blood pressure level, diastolic blood pressure level, history of angina, use of ASA, use of coumarins, use of NSAIDs, use of antidiabetic medication and a history of stroke and smoking yielded similar results and were therefore not shown. When the analysis was repeated with other antihypertensive drug classes (that is, low-ceiling diuretics, high-ceiling diuretics or calcium antagonists), there was no significant drug-gene interaction with any of these antihypertensive drug classes with either of the genotypes. Also, the additional analyses with only ischemic strokes (n ¼ 188) were nonsignificant. In addition, the exclusion of all subjects who had a stroke before 1990 yielded similar results and were therefore not shown.
A combination of the risk alleles of the two polymorphisms did not reveal any association with the risk of stroke (Table 8 ). In addition, none of the SIs were significant (b-blocker SI ¼ 1.54; 95% CI: 0.92-2.57; ACE inhibitors SI ¼ 1.29; 95% CI: 0.72-2.29), suggesting no strong drug-gene-gene interaction on the risk of stroke.
Discussion
In this study, no significant interaction was found between the use of ACE inhibitors or b-blockers and the ACE I/D polymorphism on the risk of MI or stroke. We did find an interaction between the AGTR1 573C/T polymorphism and current use of ACE inhibitors on the risk of MI. The joint effect was approximately three times smaller than expected based on their individual effects, although no allele doseresponse relationship was observed. In addition, no significant drug-gene interaction was found in ACE inhibitor users on the risk of stroke and only a borderline increased risk of stroke in current users of b-blockers with at least one copy of the C allele compared to b-blockers with the TT genotype, which was no longer significant when we only included cases with ischemic strokes. Since we had more ACE inhibitor or b-blocker users who experienced a stroke than an MI, we had more power to detect a drug-gene interaction on the risk of stroke. The combination of both risk variants of both polymorphisms did not statistically increase or decrease the risk of MI or stroke, which might be compatible not only with the absence of an interaction but also by the smaller number of MI and stroke cases with both risk alleles. Arnett et al. 2 reported that the 6-year hazard rate for fatal and non-fatal coronary heart disease in the DD genotype group was not statistically different from the ID and II genotype group in ACE inhibitor users in the GenHAT study. In our observational study, we confirmed this finding. To 4 found no significant association between the 1166A/C polymorphism and blood pressure in ACE Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, DDDs, systolic blood pressure level, diabetes mellitus, use of statins, use of ASA and history of coronary heart disease, stroke and angina.
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H Schelleman et al inhibitor users. Although we did not study the effect of the 1166A/C polymorphism, the distance between the AGTR1 1166A/C polymorphism and the 573C/T polymorphism is about 500 bp, and therefore these polymorphisms are most likely in linkage disequilibrium with each other. The risk of MI in the current ACE inhibitor users was significantly increased compared to the non-users. Confounding by indication might explain these findings. As a physician was free to choose whether a patient received antihypertensive drug treatment or not and the type of antihypertensive drug, specific patient characteristics might have influenced this decision. However, the interaction between b-blockers or ACE inhibitors and the AGTR1 573C/T polymorphism is probably not influenced by this bias, as the users of the same antihypertensive drug class will most likely have the same characteristics and the prescriber is unaware of the subject's genotype.
The main limitation of our study is the relatively small number of events. Therefore, we might have missed a drug-gene interaction with a small effect. In addition, even though current ACE inhibitor users with at least one copy of the AGTR1 573C allele had an increased risk of MI in this study, the results should still be interpreted with caution because there did not seem to be an allele doseresponse effect and the effect in b-blocker users on the risk of stroke was in the opposite direction. Therefore, these results need to be replicated in other studies before definitive conclusions can be made. In addition, owing to limited sample sizes, we were unable to test for dose-response and duration-response relationships. Another limitation is that only one polymorphism in the ACE and AGTR1 gene was investigated, and therefore we cannot exclude the possibility that another polymorphism in these genes might influence the response to ACE inhibitors or b-blockers.
In conclusion, our results indicate that the AGTR1 573CT or TT genotype might be associated with an increased risk of MI in users of ACE inhibitors, although further investigations are needed to clarify the role of this polymorphism before definitive conclusions can be made.
Materials and methods

Setting
The Rotterdam Study started in 1990 as a population-based prospective follow-up study. All 10 275 residents of the suburb Ommoord in Rotterdam, aged 55 years or older, were invited to participate. In total, 7983 (78%) subjects gave written informed consent. The baseline measurements took place until 1993. The design of this study has been described elsewhere. 5 Information was collected on age, Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, DDDs, systolic blood pressure level, diabetes mellitus, use of statins, use of ASA and history of coronary heart disease, stroke and angina.
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H Schelleman et al gender, present health status and medical history, including previous MI and stroke. All reported MIs or strokes at baseline were verified with medical records. During a physical examination, blood pressure, weight and height were measured and blood was drawn for DNA extraction.
Since the start of the Rotterdam Study, follow-up examinations have been carried out every 2-3 years.
Cohort and outcome definition
Only subjects with hypertension were included in this study from 1 January 1991. Therefore, follow-up started on the day that an elevated blood pressure was measured and/or the day that a first antihypertensive drug was prescribed, whichever came first. Blood pressure data from all three examination rounds were used to determine whether a person had hypertension. If a person had an elevated blood pressure (X160/95 mm Hg and/or treated with antihypertensive agents) during the first examination, he/she was considered hypertensive from this point on. If a person was hypertensive during the second examination, he/she was considered hypertensive from that point on. The 'old' definition of hypertension was applied due to the start of the study in 1990. MI and stroke cases between 1 January and 1 July 1991 were excluded since pharmacy records were not available before 1 January 1991, and therefore their drug history was shorter than 6 months. However, cases were not excluded if they had an MI (or stroke) before 1 January 1991 and a second MI (or stroke) after 1 July 1991 (prevalent cases). The end of the study was set at 1 January 2002. Follow-up ended on the date of the first MI (or first stroke for the analysis with stroke as primary outcome) or a censoring event (end of study period, moving out of the area or death), whichever came first. All collected coronary events were verified by a review of hospital discharge reports and letters from medical specialists and then classified as definitive and possible MI. Two research physicians independently coded events according to the International Classification of Diseases, 10th revision (ICD-10). 6 MI was defined as ICD code I21. A medical expert in cardiovascular disease also reviewed all coded events for final classification.
Stroke was defined as ICD code K90. Stroke research physicians reviewed information on all possible strokes and transient ischemic attacks; an experienced stroke neurologist verified all diagnosis. Subarachnoid hemorrhages and retinal strokes were excluded. Ischemic strokes were diagnosed when a patient had typical symptoms, and a computed tomography and magnetic resonance imaging that were made within 4 weeks ruled out other diagnoses or when indirect evidence (deficit limited to one limb or completely resolved within 72 h, atrial fibrillation in the absence of anticoagulants) pointed at an ischemic nature of stroke. Hemorrhagic stroke was diagnosed when a relevant hemorrhage was shown on computed tomography or magnetic resonance imaging scan, or when the subject permanently lost consciousness or died within hours after the onset of focal signs. If a stroke did not match these criteria, it was classified as unspecified. 7 Subclassification into hemorrhagic and ischemic stroke was based on neuroimaging, which was available for 64% of all cases.
Exposure definition
Pharmacy records were available for approximately 99% of the cohort as of 1 January 1991. These records include the name of the drug, the day of dispensing, the dosage form, the number of units dispensed, the prescribed daily dose and the Anatomical Therapeutic Chemical code of the drug. 8 The exposure of interest included ACE inhibitors and b-blockers because of their direct effect on the RAS. When an MI or stroke occurred, the date was defined as the event date and the cumulative duration of use for current and past exposure of all antihypertensive drug classes on that date was calculated for each participant. We first calculated each prescription length by dividing the number of dispensed tablets or capsules by the prescribed daily number. Each refill at the pharmacy, which occurred within 7 days after last intake from the previous prescription, was considered as a continuous drug episode. Current, past and never use were defined as mutually exclusive categories. When the event fell within a usage period, the patient was considered as currently exposed and the cumulative number of days of current use was calculated. Similarly, for those who were not current users but had used a representative of the drug group in the past, the number of days since last intake was calculated. Those who had not used the drug during the follow-up period were considered as non-users. For dose-effect associations, we used the defined daily dosages, which consist of the recommended daily dose for the hypertension indicated in an adult.
Genotyping
Genomic DNA was extracted from whole blood samples using standard methods described previously. 9 The I and D alleles of the ACE I/D polymorphism were identified on the basis of the PCR technique according to the method of Lindpaintner et al. 10 with some modifications. Because the D allele in heterozygous samples is preferentially amplified, there is a tendency of misclassification for about 4-5% of the ID to DD genotypes. For this reason, a second PCR was performed with a primer pair that recognizes an insertionspecific sequence (5 0 -TGGGACCACAGCGCCCACTAC-3 0 and 5 0 -TCGCCAGCCCTCCCATGCCCATAA-3 0 ). The reaction yielded a 335-bp amplicon only if the I allele was present. Two independent investigators read images from each gel and all ambiguous samples were analyzed a second time. The AGTR1 573 C/T polymorphism (rs5182) was genotyped with a TaqMan allelic discrimination Assays-ByDesign (Applied Biosystems, Foster City, CA, USA For the analysis with stroke as an end point, we considered the same potential confounders but combined the history of MI, history of percutaneous transluminal coronary angioplasty and history of coronary artery bypass grafting in one variable (coronary heart disease).
Statistical analyses
The outcomes for MI and stroke were analyzed separately because of their different etiology. Both events were evaluated using a Cox proportional hazard model with timevarying exposure for each antihypertensive drug class separately. We created non-cumulative time-dependent categorical variables (yes/no) for current and past use of antihypertensive drugs, and follow-up time was the time axis of the model. Non-use of ACE inhibitors (in the analysis of the association between ACE inhibitors and the risk of MI or stroke) and non-use of b-blockers (in the analysis of the association between b-blockers and the risk of MI or stroke) served as a reference. The associations were expressed as HRs with 95% CI. We adjusted for all potential confounders that caused a change in the point estimate of 10% or more.
We calculated the SI, which is the ratio of the HR in susceptibles to that in the non-susceptibles. To investigate, for example, the interaction between the ACE I/D polymorphism and ACE inhibitors, one dummy variable was added to the model: I allele (0/1) Â ACE inhibitors (0/1). An SI of 1 means that the HRs in the two subgroups are the same and that there is no interaction on a multiplicative scale. An SI greater than 1 means that the joint effect of gene and drug is larger than expected from the product of their individual effects. 11 In addition, for the drug-gene-gene analyses, we combined risk alleles (ID or II and CT or TT) of both polymorphisms and analyzed the data versus all other genotype groups (DD and CC; ID or II and CC; DD and CT or TT).
All analyses were performed using SAS version 9.1 (SAS Institute, Vary, NC, USA).
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